Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2016

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,162			—			—			—		$	18,162
Product revenues		—		$	8,001			—			—			8,001
Royalty and license fee income		—			270			—			—			270
		18,162			8,271			—			—			26,433
Operating expenses:
Cost of clinical laboratory services		11,142			—			—			—			11,142
Cost of product revenues		—			3,846			—			—			3,846
Research and development		—			674		$	208			—			882
Selling, general and administrative		6,008			2,877			—		$	1,984			10,869
Provision for uncollectible accounts receivable		612			(36	)		—			—			576
Legal fee expense		54			11			—			1,567			1,632
Legal settlements, net		—			—			—			—			—
Total operating expenses		17,816			7,372			208			3,551			28,947

Operating income (loss)		346			899			(208	)		(3,551	)		(2,514	)

Other income (expense):
Interest		(33	)		7			—			(14	)		(40	)
Other		2			4			—			16			22
Foreign exchange gain		—			419			—			—			419
Income (loss) before income taxes	$	315		$	1,329		$	(208	)	$	(3,549	)	$	(2,113	)

Depreciation and amortization included above	$	418		$	514		$	—		$	28		$	960

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		14		$	9			—		$	124			147
Total	$	16		$	9		$	—		$	124		$	149

Capital expenditures	$	331		$	115		$	—		$	—		$	446

Three months ended April 30, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	15,657			—			—			—		$	15,657
Product revenues		—		$	7,906			—			—			7,906
Royalty and license fee income		—			423			—			—			423
		15,657			8,329			—			—			23,986
Operating expenses:
Cost of clinical laboratory services		9,724			—			—			—			9,724
Cost of product revenues		—			3,779			—			—			3,779
Research and development		—			704		$	105			—			809
Selling, general and administrative		4,935			3,031			—		$	2,180			10,146
Provision for uncollectible accounts receivable		631			(42	)		—			—			589
Legal fee expense		42			(22	)		—			1,935			1,955
Legal settlement, net		—			(170	)		—			—			(170	)
Total operating expenses		15,332			7,280			105			4,115			26,832

Operating income (loss)		325			1,049			(105	)		(4,115	)		(2,846	)

Other income (expense):
Interest		(23	)		6			—			(41	)		(58	)
Other		11			2			—			13			26
Foreign exchange loss		—			(125	)		—			—			(125	)
Income (loss) before income taxes	$	313		$	932		$	(105	)	$	(4,143	)	$	(3,003	)

Depreciation and amortization included above	$	358		$	543		$	—		$	22		$	923

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	—			—			—			—
Selling, general and administrative		9			6			—		$	95			110
Total	$	12		$	6		$	—		$	95		$	113

Capital expenditures	$	453		$	58		$	—		$	4		$	515

Nine months ended April 30, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	52,775			—			—			—		$	52,775
Product revenues		—		$	22,266			—			—			22,266
Royalty and license fee income		—			1,129			—			—			1,129
		52,775			23,395			—			—			76,170
Operating expenses:
Cost of clinical laboratory services		32,009			—			—			—			32,009
Cost of product revenues		—			10,663			—			—			10,663
Research and development		—			2,002		$	608			—			2,610
Selling, general and administrative		16,943			8,709			—		$	6,722			32,374
Provision for uncollectible accounts receivable		1,787			(48	)		—			—			1,739
Legal fee expense		120			(6	)		—			5,530			5,644
Legal settlements, net		1,500			(19,950	)		—			—			(18,450	)
Total operating expenses		52,359			1,370			608			12,252			66,589

Operating income (loss)		416			22,025			(608	)		(12,252	)		9,581

Other income (expense):
Interest		(75	)		38			—			(85	)		(122	)
Other		5			35			—			47			87
Foreign exchange loss		—			(99	)		—			—			(99	)
Income (loss) before income taxes	$	346		$	21,999		$	(608	)	$	(12,290	)	$	9,447

Depreciation and amortization included above	$	1,226		$	1,568		$	—		$	68		$	2,862

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Research and development		—			—			—			—			—
Selling, general and administrative		33		$	19			—		$	313			365
Total	$	38		$	19		$	—		$	313		$	370

Capital expenditures	$	1,122		$	267		$	—		$	—		$	1,389

Nine months ended April 30, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	46,204			—			—			—		$	46,204
Product revenues		—		$	23,631			—			—			23,631
Royalty and license fee income		—			2,067			—			—			2,067
		46,204			25,698			—			—			71,902
Operating expenses:
Cost of clinical laboratory services		29,100			—			—			—			29,100
Cost of product revenues		—			11,292			—			—			11,292
Research and development		—			1,887		$	547			—			2,434
Selling, general and administrative		15,090			8,886			—		$	6,125			30,101
Provision for uncollectible accounts receivable		1,820			(89	)		—			—			1,731
Legal fee expense		174			(74	)		—			7,125			7,225
Legal settlement, net		—			(170	)		—			—			(170	)
Total operating expenses		46,184			21,732			547			13,250			81,713

Operating income (loss)		20			3,966			(547	)		(13,250	)		(9,811	)

Other income (expense):
Interest		(63	)		13			—			(126	)		(176	)
Other		18			(34	)		—			44			28
Foreign exchange loss		—			(856	)		—			—			(856	)
Income (loss) before income taxes	$	(25	)	$	3,089		$	(547	)	$	(13,332	)	$	(10,815	)

Depreciation and amortization included above	$	1,072		$	1,656		$	2		$	67		$	2,797

Share-based compensation included in above:
Cost of clinical laboratory services	$	9			—			—			—		$	9
Research and development		—		$	2			—			—			2
Selling, general and administrative		30			9			—		$	269			308
Total	$	39		$	11		$	—		$	269		$	319

Capital expenditures	$	1,042		$	122		$	—		$	4		$	1,168